I hereby certify that this correspondence is being deposited with the United States Postal Service on the date set forth below as First Class Mail in an envelope addressed to: Commissioner for Patents, P O Box 2327, Arlington, VA 22202.

IN THE UNITED STATES PATENT AND TRADEMARK OFF

Applicants:

Teresa Compton

Mary T. Huber

ate of Signature and Deposit: September 6, 2002

Serial No.: 09/942,146

Filed: August 29, 2001

Title: HUMAN CYTOMEGALOVIRUS

GLYCOPROTEIN O AS A NEW DRUG

TARGET AND SUBUNIT VACCINE CANDIDATE

Date: September 6, 2002

Zhibin Ren

Cassa Ant I Init. 1649

Group Art Unit: 1648

Examiner: --

File No.: 960296.98342

RECEIVED

DEC 1 3 2002

INFORMATION DISCLOSURE STATEMENT

TECH CENTER 1600/2900

Commissioner for Patents P O Box 2327 Arlington, VA 22202

Dear Sir:

Enclosed is a completed Form PTO-1449 listing documents which the applicants in the aboveidentified application wish to bring to the attention of the Examiner for consideration in connection with the examination on the merits of this application.

This application is a divisional application of US Application No. 09/627,986, filed July 28, 2000. Under 37 C.F.R. § 1.98(d), copies of documents that were earlier cited by or submitted to the Office in a prior application that is relied on for an earlier effective filing date do not have to be submitted. The documents listed on the Form PTO-1449 were either previously cited by or submitted to the Office in US Application No. 09/627,986. Accordingly, copies of these documents are not included herein.

No fee is believed due in connection with this submission. However, should any fee be due, please charge the fee to Deposit Account No. 17-0055.

Respectfully submitted,

Zhibin Ren

Reg. No. 47,897

Quarles & Brady LLP

P O Box 2113

Madison, WI 53701-2113

(608) 251-5000

(608) 251-9166

SEP 1 8 2002
OFFICE OF PETITIONS

PTO/SB/08A (10-01) Approvior use through 10/3D/DA (10-01)

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under Se Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

		44404 (DTO			Complete If Known				
1	Substitute for form	1449A/PTO			Application Number	09/942-146 8/29/2654H CENTER 1600/29			
/ U]	- ONEO	RMATION D	isci o	CLIDE	Filing Date	8/29/200411 CENTER 1000/2300			
	<u> </u>	CINALION D	ADDI	CANT	First Named Inventor	Teresa Compton			
SEP	TATEMENT BY APPLICANT (use as many sheets as necessary)				Group Art Unit	1648			
	<u> </u>	se as many sneets	as neces	saiy)	Examiner Name				
Er.	Sheet	1	of	2	Attorney Docket Number	960296.98342			
\ G 7-									

				U.S	. PAT	ENT DOCUMENTS			
Examiners Initial	Cite No. 1		S. Patent Docum	ent Kind Code²		Name of Patentee or Applicant Of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Line Relevant Passages Or Figures Appea	Relevant
		5,011,82	9		Hirse	ch, et al.	4/30/1991		
		5,149,52		l	Ho,	•	9/22/1992		i
		5,171,56				te, et al.	12/15/1992		l l
		5,244,79				ke, et al.	9/14/1993	DEC	
		5,477,03		ŀ		naque, et al.	12/19/1995	REU	EIVE
		5,612,04				ke, et al.	3/18/1997		
		5,648,07				xe, et al.	7/15/1997	DEC	1 3 2002
		5,750,106			Ostb	perg	5/12/1998	5/12/1998 5/12/1998 6/2/1998 6/9/1998 TECH CENTER 1600/	
	5,750,106 5,750,114 5,759,814 5,763,161				1	ke, et al.	5/12/1998		
				- 1		ke, et al.	1 1		
				1		hara, et al.			
		5,795,57				ke, et al.	8/18/1998		1
		5,800,98				geman, et al.	9/1/1998		
	5,807,557 5,837,261 5,853,734			Dubin Inglis, et al.		9/15/1998	/15/1998		
						11/17/1998	11/17/1998		
				Cha	ng, et al.	12/29/1998			
				FORE	IGN P	ATENT DOCUMENTS			
Examiner	Foreign Patent Doc			Code⁵	Name of Patentee or	Date of Publication of Cited Document	Pages, Columns, Lines, Where Relevant Passages	т•	
Initials*	No. 1	Office ³ Number ⁴			nown)	Applicant of Cited Document	MM-DD-YYYY	or Relevant Figures Appear	
		C	THER PRI	OR ART –	NON	PATENT LITERATURE	DOCUMENTS		
Examiner Initials*	Cit No				urnal, sei	APITAL LETTERS), title of the article rial, symposium, catalog, etc.), date, sher, city and/or country where publis	page(s), volume-issue nu		T 6
			LE, K. A., cellular Sig			otein B of Human Cyto act).	megalovirus El	icits	
			ER, M. T., H/gL Com			CMV UL74 Gene Encodt).	des the Third C	omponent of	
		Cyto	ER, M. T., megaloviru , 1997.	et al., "C us Glycop	harac roteir	terization of a Novel T n H-Glycoprotein L Cor	hird Member of mplex," J. Virol.	the Human , 71(7):5391- RECEL	

		SED 1	
EXAMINER	DATE	1 8 200	117
SIGNATURE	CONSIDERED	OFFICE	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if holiaconformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

QBMAD/340010_1.pdf

PTO/SB/08A (10-01)

Applied for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Repervork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

State titute for form 1449A/PTO			Compi	lete If Known
1445/41 10			Application Number	09/942,146
MATION	DISCI OS	URF	Filing Date	8/29/2001
			First Named Inventor	Teresa Controton 6° 20
			Group Art Unit	1648 17 CENTS
			Examiner Name	1600 IR
2	of	2	Attorney Docket Number	960296.98342
	MATION EMENT B	RMATION DISCLOS EMENT BY APPLIC as many sheets as necessary	RMATION DISCLOSURE EMENT BY APPLICANT of as many sheets as necessary)	RMATION DISCLOSURE EMENT BY APPLICANT To as many sheets as necessary) Filing Date First Named Inventor Group Art Unit Examiner Name

	HUBER, M. T., et al., "The Human Cytomegalovirus UL74 Gene Encodes the Third Component of the Glycoprotein H-Glycoprotein L-Containing Envelope Complex," J. Virol. 72(10):8191-8197, 1998.	
	HUBER, M. T., et al., "Intracellular Formation and Processing of the	
	Heterotrimeric gH-gL-gO (gCIII) Glycoprotein Envelope Complex of Human	ļ
	Cytomegalovirus," J. Virol. 73(5):3886-3892, 1999.	
	PIETROPAOLO, R., "Direct Interaction between Human Cytomegalovirus Glycoprotein B and Cellular Annexin II," J. Virol. 71(12):9803-9807, 1997.	
	RECEIVED	þ
	DEC 1 3 2002	
	TECH CENTER 1600/2	900
		·

EXAMINER	
SIGNATURE	

DATE

CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and hot IONS

considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231